GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Dexamethason (ATC-Code nach WHO: S01BA01)

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

February 28, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), by way of an open-house model for the active ingredient dexamethasone (ATC code according to WHO: S01BA01)

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedDecember 23, 2025
Procurement stageActive solicitation
Response dueFebruary 28, 2027
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedSeptember 21, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Dimethylfumarat, ATC D05BX02 für die Zeit 01.01.2026 - 31.12.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Teriflunomid, ATC L04AK02 für die Zeit 01.10.2025 - 31.12.2025 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol, Beclometason, Glycopyrronium, f. d. Z. 01.11.25 - 31.10.26 (zzgl. Verlängerungsoption 1x12 Mon)
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient Tildrakizumab, ATC L04AC17, for the period 01.01.2026 - 31.12.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Guanfacin, ATC N06BA21 für die Zeit 01.01.2026 - 31.12.2027 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Cladribin (OBO), ATC L04AA40 für die Zeit 01.12.2024 - 30.11.2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Glecaprevir und Pibrentasvir, ATC J05AP57 für die Zeit 01.09.2025 - 31.08.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon beta-1a, ATC L03AB13 für die Zeit 01.01.2026 - 31.12.2027

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.